Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy. | MicrobiomeTrials← Back to trialsNCT07736911
Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06-01Est. Completion: 2029-06-01
Enrollment target: 140 participants Locations- FJUH, New Taipei City, Taiwan, Taiwan
Other microbiome trials you might be interested in
Gastrointestinal Disease Symptoms
The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebioti…
Fort Collins, United StatesCompleted Aug 1, 2026
Grade 1 Endometrial Endometrioid CarcinomaEndometrial Intraepithelial NeoplasiaMetabolic Comorbidities
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with…
Hershey, United StatesEst. completion May 1, 2028
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating mode…
Long Beach, United StatesEst. completion Mar 31, 2029